President Donald Trump is once again challenging entrenched interests in the healthcare industry, this time targeting Pharmacy Benefit Managers (PBMs) and their role in driving up prescription drug costs. Trump’s declaration to “knock out the middleman” has sent shockwaves through the pharmaceutical and health insurance markets, underscoring his commitment to reforming an opaque system that many argue disproportionately benefits intermediaries at the expense of consumers.
Dr. Peter McCullough Calls On Trump to REPEAL the 1986 Vaccine Injury Act
This would strip Big Pharma of its liability shield, making them accountable for injuries caused by their products.
“Americans deserve safe vaccines. And when they are applied, the company should stand… pic.twitter.com/mY14t9tS5z
— The Vigilant Fox 🦊 (@VigilantFox) November 11, 2024
Trump’s comments were made as part of his broader initiative to tackle soaring healthcare expenses, specifically targeting PBMs, which act as intermediaries between drug manufacturers, insurers, and pharmacies.
The former president asserted that PBMs are inflating drug prices by pocketing hefty rebates while patients see little to no reduction in their out-of-pocket costs. “We’re going to knock out the middleman,” Trump stated, as reported by Breitbart. “That middleman is making a fortune, and we’re going to bring those savings to the American people.”
Trump’s stance has had an immediate financial impact, as shares of major health insurers and PBM-affiliated corporations tumbled following his remarks. According to MSN, companies like CVS Health, UnitedHealth Group, and Cigna saw significant declines in their stock prices, signaling investor concern over the potential for sweeping regulatory reforms.
Pfizer CEO Albert Bourla confirmed Trump’s focus on PBM reform, further emphasizing that the pharmaceutical supply chain’s current structure is unsustainable and in need of serious recalibration.
claiming to negotiate lower drug prices on behalf of insurers and consumers while retaining large portions of the rebates they secure. Trump’s critique aligns with longstanding conservative arguments that PBMs exploit their position for profit rather than prioritizing savings for patients.
By eliminating or reforming this middleman structure, Trump argues, Americans could see substantial reductions in the price of life-saving medications.
Conservative analysts have applauded Trump’s move, pointing out that PBMs are yet another example of bureaucratic inefficiency artificially driving up costs in the healthcare system.
While Democrats have historically resisted substantive PBM reforms, conservatives have long argued for increased transparency and free-market solutions to drive down costs.
Trump’s remarks reflect a broader conservative philosophy: that healthcare costs can be reduced not through government control but by addressing inefficiencies within the private sector.
STOP PUTTING INTO YOUR BODY ANYTHING THAT GOD DIDN’T PUT THERE👊. Big Pharma is just trying to make you sick because there’s billions in it for them🤬. This post would of gotten me the 🥾 if it wasn’t for @elonmusk 🇺🇸 pic.twitter.com/u1ezHHRvvX
— Bobby D🎙 (@robertdunlap947) December 16, 2024
